3 days Ago By ABMN Staff
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC – Free Report ) – Research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Fulcrum Therapeutics in a report released on Thursday, September 12th. Leerink Partnrs analyst J.
Schwartz now forecasts that the company will post earnings per share of ($0.32) for the year, up from their previous estimate of ($0.43).
Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.48) per share.
Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.
30) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.
17) EPS and FY2026 earnings at ($1.06) EPS. Fulcrum Therapeutics ( NASDAQ:FULC – Get Free Report ) last issued its earnings results on Wednesday, July 31st.
The company reported $0.87 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.
93. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.
28%. The company had revenue of $80.00 million during the quarter, compared to analysts’ expectations of $80.
00 million. During the same quarter in the previous year, the company posted ($0.38) EPS.
Get Our Latest Report on FULC Fulcrum Therapeutics Trading Down 7.6 % NASDAQ FULC opened at $3.18 on Monday.
Fulcrum Therapeutics has a 12 month low of $2.87 and a 12 month high of $13.70.
The company has a market capitalization of $197.65 million, a PE ratio of -1.99 and a beta of 2.
23. The stock has a 50-day simple moving average of $8.41 and a 200 day simple moving average of $8.
26. Institutional Investors Weigh In On Fulcrum Therapeutics Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc.
boosted its position in Fulcrum Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc.
now owns 2,538,665 shares of the company’s stock worth $23,965,000 after acquiring an additional 18,681 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Fulcrum Therapeutics by 13.5% during the second quarter.
Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock worth $9,182,000 after purchasing an additional 176,114 shares during the last quarter. Vestal Point Capital LP bought a new position in Fulcrum Therapeutics in the fourth quarter valued at $6,919,000. ADAR1 Capital Management LLC acquired a new stake in Fulcrum Therapeutics in the 4th quarter valued at $4,302,000.
Finally, Jane Street Group LLC lifted its position in Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after buying an additional 188,212 shares in the last quarter.
Institutional investors and hedge funds own 89.83% of the company’s stock. Fulcrum Therapeutics Company Profile ( Get Free Report ) Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. See Also Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
